Health
Pfizer aims for $15bn in 2021 COVID-19 vaccine sales – PMLiVE
Current estimate is based on already agreed contracts
Pfizer has forecast major sales expectations for its BioNTech-partnered COVID-19 vaccine, BNT162b2, in its fourth quarter results – aiming for approximately $15bn in revenues for 2021.
The company said that the 2021 guidance for the vaccine mainly includes doses that are expected to be delivered in the year under existing contracts, adding that it may be adjusted dependent on future additional contracts.
In the fourth quarter of 2020 alone BNT162b2 contributed $154m to Pfizer’s overall sales.
For…
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
General24 hours agoLiberals dump NSW candidate who said women should not serve in ADF combat
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts